Alendronate alleviates the symptoms of experimental autoimmune encephalomyelitis.
Alendronate
/ pharmacology
Animals
Anti-Inflammatory Agents
/ pharmacology
Cell Proliferation
/ drug effects
Cytokines
/ genetics
Encephalomyelitis, Autoimmune, Experimental
/ drug therapy
Female
Mice, Inbred C57BL
Multiple Sclerosis
/ drug therapy
Nitric Oxide Synthase Type II
/ immunology
Spinal Cord
/ drug effects
T-Lymphocytes
/ drug effects
Alendronate
Experimental autoimmune encephalomyelitis
Inflammation
Mevalonate cascade
Multiple sclerosis
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
04
02
2020
revised:
06
04
2020
accepted:
20
04
2020
pubmed:
4
5
2020
medline:
16
3
2021
entrez:
4
5
2020
Statut:
ppublish
Résumé
Nitrogen-containing bisphosphonates, such as alendronate, have been widely used to treat osteoporosis because they may target multiple signals in the mevalonate cascade. The present study evaluated the therapeutic effects of alendronate on experimental autoimmune encephalomyelitis (EAE), which is a prototypical autoimmune disease model. EAE was induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein (MOG)
Identifiants
pubmed: 32361191
pii: S1567-5769(20)30312-X
doi: 10.1016/j.intimp.2020.106534
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Cytokines
0
Nitric Oxide Synthase Type II
EC 1.14.13.39
Nos2 protein, mouse
EC 1.14.13.39
Alendronate
X1J18R4W8P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106534Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.